DNTH Quote, Financials, Valuation and Earnings

Ocugen, Inc. has a net margin of -22687.32% compared to Dianthus Therapeutics, Inc.'s net margin of -1144.46%. Dianthus Therapeutics, Inc.'s return on equity of -40.1% beat Ocugen, Inc.'s return on equity of -848.82%.

Dianthus Therapeutics, Inc. has a consensus price target of $119.55, signalling upside risk potential of 50.88%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.04 which suggests that it could grow by 444.34%. Given that Ocugen, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Ocugen, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.750, suggesting its more volatile than the S&P 500 by 175.048%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $284K, which are larger than Ocugen, Inc. quarterly revenues of -$193K. Dianthus Therapeutics, Inc.'s net income of -$64.4M is lower than Ocugen, Inc.'s net income of -$17.7M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 1,501.89x versus 112.89x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cartesian Therapeutics, Inc. has a net margin of -22687.32% compared to Dianthus Therapeutics, Inc.'s net margin of -9775.71%. Dianthus Therapeutics, Inc.'s return on equity of -40.1% beat Cartesian Therapeutics, Inc.'s return on equity of --.

Dianthus Therapeutics, Inc. has a consensus price target of $119.55, signalling upside risk potential of 50.88%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.57 which suggests that it could grow by 294.36%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.183%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $284K, which are smaller than Cartesian Therapeutics, Inc. quarterly revenues of $947K. Dianthus Therapeutics, Inc.'s net income of -$64.4M is higher than Cartesian Therapeutics, Inc.'s net income of -$92.6M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 1,501.89x versus 80.48x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of -22687.32% compared to Dianthus Therapeutics, Inc.'s net margin of 57.24%. Dianthus Therapeutics, Inc.'s return on equity of -40.1% beat Royalty Pharma Plc's return on equity of 13.52%.

Dianthus Therapeutics, Inc. has a consensus price target of $119.55, signalling upside risk potential of 50.88%. On the other hand Royalty Pharma Plc has an analysts' consensus of $51.56 which suggests that it could grow by 12.47%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Dianthus Therapeutics, Inc. is more attractive than Royalty Pharma Plc.

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.666%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Royalty Pharma Plc offers a yield of 1.95% to investors and pays a quarterly dividend of $0.24 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 49.4% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dianthus Therapeutics, Inc. quarterly revenues are $284K, which are smaller than Royalty Pharma Plc quarterly revenues of $622M. Dianthus Therapeutics, Inc.'s net income of -$64.4M is lower than Royalty Pharma Plc's net income of $356M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Royalty Pharma Plc's PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 1,501.89x versus 10.26x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -22687.32% compared to Dianthus Therapeutics, Inc.'s net margin of -360.68%. Dianthus Therapeutics, Inc.'s return on equity of -40.1% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Dianthus Therapeutics, Inc. has a consensus price target of $119.55, signalling upside risk potential of 50.88%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $41.70 which suggests that it could grow by 17.53%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Dianthus Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.082%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $284K, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Dianthus Therapeutics, Inc.'s net income of -$64.4M is lower than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 53.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 1,501.89x versus 10.07x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.